Preview

Systemic Hypertension

Advanced search

Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine

Abstract

Objective - to estimate the quality of life with therapy of trimetazidine in patients with idiopathic pulmonary hypertension, I-III functional class. Material and methods. In this study we included 29 patients (27 women and 2 men) aged 41.9±10 years. All patients had a common complain of angina-like symptoms. The patients were divided into 2 groups. The first group consisted of 11 patients (1 men and 10 women) who were additionally prescribed trimetazidine 35 mg twice daily for 24 weeks. The second group included 18 patients (1 men and 17 women) who continued to receive standard and specific therapy. At baseline and after 24 weeks all patients were examination, which included: laboratory (general and biochemical blood tests, D-dimer), clinical and instrumental examinations (electrocardiography, echocardiography, chest radiography, scintigraphy, a 6-min walking test, spirometry). We are take into consideration: age, sex, functional class (World Health Organization), complaints, tolerance, a 6-min walking test, Holter electrocardiogram in 12 lead, SF-36 questionnaire. Results. We analyzed the questionnaire SF-36 quality of life compared to before and after treatment trimetazidine: improvement in general health (p<0.02), physical role functioning (p<0.02), improvement index bodily pain (p<0.01), Vitality (p<0.02), mental health (p<0.01). Our study showed that the SF-36 questionnaire reliably describes the patient's physical, social and mental condition. Conclusion. Trimetazidine therapy improves quality of life in patients with idiopathic pulmonary hypertension, complaining of chest pain.

About the Authors

E. G. Kuznetsova
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


S. I. Glukhova
V.A.Nasonova Research Institute of Rheumatology
Russian Federation


T. V. Martynyuk
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


S. N. Nakonechnikov
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


I. E. Chazova
National Medical Research Center for Cardiology of the Ministry of Health of the Russian Federation
Russian Federation


References

1. Galie N, Humbert M, Vachiery J.L et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J 2015; 46 (4): 903-75.

2. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевт. арх. 2014; 9: 4-23.

3. Hoeper M, Bogaard H.J, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): 42-50.

4. Белов В.Н. Оценка качества жизни в коронарной хирургии. Вестн. эксперим. и клин. хирургии. 2010; 3 (4): 384-7.

5. Sullivan M et al. The reproducibility of hemodynamic, electrocardiographic, and gas exchange data during treadmill exercise in patients with stable angina pectoris. Chest 1984; 86: 375-82.

6. Mc Laughlin V.V, Archer S, Badesch D.B et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force of Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.

7. Gibbs J.S. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008; 63 (Suppl. II): 1-41.

8. Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010; 159: 245-57.

9. Sitbon O, Humbert M, Jais X et al. Long - term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.

10. Шилов А.М., Осия А.О. Антигипоксанты и антиоксиданты с метаболическим действием (триметазидин) при ишемической миокардиопатии. Рус. мед. журн. 2010; 18 (10): 663-7.

11. Белардинелли Р. Благоприятные эффекты метаболического подхода в реабилитации пациентов с заболеваниями сердца. Сердце и метаболизм. Эффективность сердечной деятельности в норме и при заболеваниях. 2009; 23: 21-4.

12. Морозова Т.Е. Метаболические лекарственные вещества в кардиологической практике. Лечащий врач. 2008; 6: 48-51.

13. Метелица В.И. Справочник по клинической фармакологии сердечно - сосудистых лекарственных средств. 2002; с. 171-6.

14. Astarie-Dequeker C, Joulin Y, Devynck M.A. Inhibitory effect of trimetazidine on thrombin - induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994; 23: 401-7.

15. Belcher P.R, Drake-Holland A.J, Hynd J.W et al. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993; 7: 149-57.

16. Kim J. Effect of trimetazidine therapy in AMI patients: from Korean Acute Miocardial Infarction registry (KMIR). WCC-12-ABS-1621.

17. Di Napoli P, Di Giovanni P, Gaeta M.A et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischаemic dilated cardiomyopathy: a post hoc analysis of the Villa Pinid'AbruzzoTrimetazidine Trial. J Cardiovasc Pharmacol 2007; 50 (5): 585-9.

18. Согласованное мнение экспертов о целесообразности использования миокардиального цитопротектора триметазидина (Предуктала МВ) в комплексной терапии больных с хроническими формами ишемической болезни сердца. Соврем. мед. технологии. 2012; 9: 52-3.

19. Задионченко В.С., Шехян Г.Г., Ялымов А.А и др. Микроциркуляция и морфофункциональный статус больных хронической сердечной недостаточностью при лечении триметазидином. Кардиоваск. терапия и профилактика. 2004; 3 (5): 74-80.

20. Shafazand S, Goldstein M.K, Doyle R.L et al. Health - related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126: 1452-9.

21. Ware J.Е, Snow K.K, Kosinski М, Gandek В. Sf-36 Health Survey. Manuel and Interpretation Guide, Lincoln, RI'. Quality Metric Incorporated, 2000; p. 150.

22. The WHOOL group. Development of the World Health Organization WHOQOLBREF quality of life assessment. Psychol Med 1998; 3: 551-8.

23. Pulido T, Adzerikho I, Channick R.N et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369 (9): 809-18.

24. Olschevski H, Simonneau G, Galie N et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.

25. Mc Laughlin V.V, Benza R.L. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol 2010; 55 (18). DOI: 10.1016/j.jacc.2010.01.027

26. Ware J.E.J, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol 1998; 51: 903-12.

27. Galen Research. Measures database. CAMPHOR - Language Adaptations Available. www.galen-research.com/measures-database/

28. Galiè N, Olschewski H, Oudiz R.J. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double - blind, placebo - controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117 (23): 3010-9. DOI: 10.1161/CIRCULATIONAHA.107.742510

29. Simonneau G, Rubin L.J, Galiè N et al. Addition of sildenafil to long - term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2006; 150 (1): 63.

30. Rubin L.J, Fleming T, Galiè N et al. Long - term treatment with sildenafil citrate in pulmonary arterial hypertension. CHEST 2011; 140 (5): 1274-83.

31. Galiè N, Rubin U, Jansa P et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double - blind, randomized, controlled trial. Lancet 2008; 371: 2093-100.


Review

For citations:


Kuznetsova E.G., Glukhova S.I., Martynyuk T.V., Nakonechnikov S.N., Chazova I.E. Quality of life in patients with idiopathic pulmonary hypertension: the first experience of trimetazidine. Systemic Hypertension. 2017;14(2):57-64.

Views: 170


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)